Bluemount vs Sangrix
BMHL and SGRX side by side, both in finance services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMHL and SGRX compare
Sangrix scores higher on the StockData Score (5 against 1 for Bluemount), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMHL | SGRX |
|---|---|---|
| Size and price | ||
| Share price | $3.14 | $2.56 |
| Change, 1 year | −10.2% | −99.6% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 0.22 | 1.40 |
| Employees | 9 | 1 |
| StockData Score | ||
| Total score | 1 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 15.4% | – |
| Profitability | ||
| Gross margin | 25.9% | – |
| Return on invested capital | – | −286% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | – | 6.98 |
| Ownership | ||
| Held by institutions | 0.19% | – |
| Held by insiders | 19.4% | – |
Go deeper
- BMHL stock overview
- BMHL income statement
- BMHL valuation and score
- SGRX stock overview
- SGRX income statement
- SGRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.